Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: Impact of psychiatric co-morbidity

Addiction Biology

Volumn 18, Issue 6, 2013, Pages 955-969

  Pavõn, Francisco Javier ^a   Araos, Pedro ^a   Pastor, Antoni ^b,c   Calado, Montserrat ^a   Pedraz, María ^a   Campos Cloute, Rafael ^d   Ruiz, Juan Jesús ^e   Serrano, Antonia ^a   Blanco, Eduardo ^a,f   Rivera, Patricia ^a   Suárez, Juan ^a   Romero Cuevas, Miguel ^a   Pujadas, Mitona ^b,g   Vergara Moragues, Esperanza ^h   Gornemann, Isolde ^a   Torrens, Marta ^b,c,i   De La Torre, Rafael ^b,g,j   Rodríguez De Fonseca, Fernando ^a,g  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Centro Comarcal de Drogodependencias   (Spain)

^e Centro de Tratamiento Ambulatorio   (Spain)

^f UNIVERSITY OF MÁLAGA   (Spain)

^g Instituto de Salud Carlos III   (Spain)

^h UNIVERSITY OF GRANADA   (Spain)

ⁱ Institut de Neuropsiquiatria i Addiccions (INAD) Del Parc de Salut MAR   (Spain)

^j UNIVERSITAT POMPEU FABRA   (Spain)

more..

Author keywords

Abuse; cocaine; dependence; DSM IV TR; endocannabinoid; psychiatric co morbidity

Indexed keywords

ACYLGLYCEROL; COCAINE; ENDOCANNABINOID; ETHANOLAMINE; ETHANOLAMINE DERIVATIVE; GLYCEROL;

ADULT; ALCOHOL USE DISORDER; ANXIETY DISORDER; ARTICLE; BLOOD LEVEL; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED STUDY; DRUG WITHDRAWAL; DSM-IV-TR; EXPLANATORY VARIABLE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTPATIENT; PRIORITY JOURNAL; SEMI STRUCTURED INTERVIEW; SUBSTANCE ABUSE; TANDEM MASS SPECTROMETRY;

ABUSE; COCAINE; DEPENDENCE; DSM-IV-TR; ENDOCANNABINOID; PSYCHIATRIC CO-MORBIDITY;

ADULT; AMBULATORY CARE; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; COCAINE-RELATED DISORDERS; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); ENDOCANNABINOIDS; ETHANOLAMINES; FATTY ACIDS, MONOUNSATURATED; FEMALE; GLYCERIDES; HUMANS; INTERVIEW, PSYCHOLOGICAL; LOGISTIC MODELS; MALE; MENTAL DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; ROC CURVE; SEVERITY OF ILLNESS INDEX; TANDEM MASS SPECTROMETRY;

EID: 84889239685     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12107     Document Type: Article

References (58)

1. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R, (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353: 23-31. (Pubitemid 28352285)
2. Ben-Shahar O, Sacramento AD, Miller BW, Webb SM, Wroten MG, Silva HE, Caruana AL, Gordon EJ, Ploense KL, Ditzhazy J, Kippin TE, Szumlinski KK, (2013) Deficits in ventromedial prefrontal cortex group 1 metabotropic glutamate receptor function mediate resistance to extinction during protracted withdrawal from an extensive history of cocaine self-administration. J Neurosci 33: 495-506a.
3. Bilbao A, Blanco E, Luque-Rojas MJ, Suarez J, Palomino A, Vida M, Araos P, Bermudez-Silva FJ, Fernandez-Espejo E, Spanagel R, Rodriguez de Fonseca F, (2013) Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARalpha receptor-independent mechanism. Addict Biol 18: 78-87.
4. Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH, (2007) Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 27: 3695-3702. (Pubitemid 46557675)
5. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V, (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2: 5.
6. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, Vanderschuren LJ, Schoffelmeer AN, (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7: 1151-1154. (Pubitemid 33010025)
7. Deschaux O, Vendruscolo LF, Schlosburg JE, Diaz-Aguilar L, Yuan CJ, Sobieraj JC, George O, Koob GF, Mandyam CD, (2012) Hippocampal neurogenesis protects against cocaine-primed relapse. Addict Biol. doi: 10.1111/adb.12019.
8. Desfosses J, Stip E, Bentaleb LA, Lipp O, Chiasson JP, Furtos A, Venne K, Kouassi E, Potvin S, (2012) Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the 'mirror effect' of schizophrenia. Front Psychiatry 3: 85.
9. Di Marzo V, Deutsch DG, (1998) Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 5: 386-404. (Pubitemid 29075840)
10. Diercks DB, Fonarow GC, Kirk JD, Jois-Bilowich P, Hollander JE, Weber JE, Wynne J, Mills RM, Yancy C, Peacock WF, 4th (2008) Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol 102: 1216-1219.
11. Editorial team (2010) The EMCDDA annual report 2010: the state of the drugs problem in Europe. Euro Surveill 15: 19714.
12. Fernandez-Ruiz J, Hernandez M, Ramos JA, (2010) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16: e72-e91.
13. Ferrer B, Bermudez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodriguez de Fonseca F, (2007) Regulation of brain anandamide by acute administration of ethanol. Biochem J 404: 97-104. (Pubitemid 46788089)
14. Feuerecker M, Hauer D, Gresset T, Lassas S, Kaufmann I, Vogeser M, Briegel J, Hornuss C, Chouker A, Schelling G, (2012) Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans. Alcohol Alcohol 47: 226-232.
15. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D, (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425: 90-93. (Pubitemid 37101723)
16. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D, (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2: 358-363. (Pubitemid 30491279)
17. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D, (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108-2114. (Pubitemid 39486563)
18. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA, (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954: 73-81. (Pubitemid 35223443)
19. Hansen HS, (2010) Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 224: 48-55.
20. Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R, (2006) Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 163: 689-696. (Pubitemid 44464580)
21. Hasin DS, Fenton MC, Beseler C, Park JY, Wall MM, (2012) Analyses related to the development of DSM-5 criteria for substance use related disorders: 2. Proposed DSM-5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients. Drug Alcohol Depend 122: 28-37.
22. Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT, (2008) Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction 103: 284-293.
23. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ, (2008) Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41: 48-53. (Pubitemid 351427522)
24. Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS, (2009) Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 287: 212-215.
25. Karila L, Petit A, Lowenstein W, Reynaud M, (2012) Diagnosis and consequences of cocaine addiction. Curr Med Chem 19: 5612-5618.
26. Kaufmann I, Schelling G, Eisner C, Richter HP, Krauseneck T, Vogeser M, Hauer D, Campolongo P, Chouker A, Beyer A, Thiel M, (2008) Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 33: 676-685.
27. Kaufmann I, Hauer D, Huge V, Vogeser M, Campolongo P, Chouker A, Thiel M, Schelling G, (2009) Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report. Eur Surg Res 43: 325-329.
28. Koppel J, Bradshaw H, Goldberg TE, Khalili H, Marambaud P, Walker MJ, Pazos M, Gordon ML, Christen E, Davies P, (2009) Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids Health Dis 8: 2.
29. Liu HS, Chefer S, Lu H, Guillem K, Rea W, Kurup P, Yang Y, Peoples L, Stein EA, (2013) Dorsolateral caudate nucleus differentiates cocaine from natural reward-associated contextual cues. Proc Natl Acad Sci USA 110: 4093-4098.
30. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D, (2005) The search for the palmitoylethanolamide receptor. Life Sci 77: 1685-1698. (Pubitemid 41073662)
31. Mangieri RA, Hong KI, Piomelli D, Sinha R, (2009) An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl) 205: 63-72.
32. Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, Fadda P, Barnes C, Redhi GH, Yasar S, Le Foll B, Tanda G, Piomelli D, Goldberg SR, (2011) Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 69: 633-641.
33. Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G, Piazza PV, Cota D, (2012) Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS ONE 7: e42399.
34. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V, (2005) Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30: 1216-1221. (Pubitemid 40720981)
35. Morgello S, Holzer CE 3rd, Ryan E, Young C, Naseer M, Castellon SA, Frol AB, Atkinson JH, Gelman BB, Grant I, Singer EJ, (2006) Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium. Int J Methods Psychiatr Res 15: 131-138. (Pubitemid 47047004)
36. Orio L, Pavon FJ, Blanco E, Serrano A, Araos P, Pedraz M, Rivera P, Calado M, Suarez J, de Fonseca FR, (2013) Lipid transmitter signaling as a new target for treatment of cocaine addiction: new roles for acylethanolamides and lysophosphatidic acid. Curr Pharm Des [Epub ahead of print].
37. Pavõn FJ, Serrano A, Romero-Cuevas M, Alonso M, Rodríguez de Fonseca F, (2010) Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications. Drug Discov Today Dis Mech 7: e175-e183.
38. Plaza-Zabala A, Berrendero F, Suarez J, Bermudez-Silva FJ, Fernandez-Espejo E, Serrano A, Pavon FJ, Parsons LH, De Fonseca FR, Maldonado R, Robledo P, (2010) Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse 64: 379-389.
39. Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF, Gendron A, Astarita G, Piomelli D, Stip E, (2008) Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol 22: 262-269. (Pubitemid 351847449)
40. Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F, Schindler TH, (2011) Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 32: 1369-1378.
41. Razzouk D, Bordin IA, Jorge MR, (2000) Comorbidity and global functioning (DSM-III-R Axis V) in a Brazilian sample of cocaine users. Subst Use Misuse 35: 1307-1315. (Pubitemid 30418852)
42. Riddle EL, Fleckenstein AE, Hanson GR, (2005) Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7: E847-E851.
43. Rivera P, Luque-Rojas MJ, Pastor A, Blanco E, Pavon FJ, Serrano A, Crespillo A, Vida M, Grondona JM, Cifuentes M, Bermudez-Silva FJ, de la Torre R, de Fonseca FR, Suarez J, (2013a) Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats. Eur J Neurosci 37: 105-117.
44. Rivera P, Miguens M, Coria SM, Rubio L, Higuera-Matas A, Bermudez-Silva FJ, de Fonseca FR, Suarez J, Ambrosio E, (2013b) Cocaine self-administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis vs. Fischer 344 rats. Int J Neuropsychopharmacol 16: 1277-1293.
45. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, Sartorius N, Towle LH, (1988) The Composite International Diagnostic Interview-an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45: 1069-1077. (Pubitemid 19005460)
46. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M, (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40: 2-14.
47. Schmid HH, Berdyshev EV, (2002) Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids 66: 363-376. (Pubitemid 34743609)
48. Schule C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R, (2011) Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience 191: 55-77.
49. Schwarz E, Whitfield P, Nahnsen S, Wang L, Major H, Leweke FM, Koethe D, Lio P, Bahn S, (2011) Alterations of primary fatty acid amides in serum of patients with severe mental illness. Front Biosci (Elite Ed) 3: 308-314.
50. Serrano A, Parsons LH, (2011) Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 132: 215-241.
51. Siegmund SV, (2010) Role of the endocannabinoid system in alcoholic liver disease. Dig Dis 28: 751-755.
52. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J, (2010) Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE 5: e8792.
53. Syed SK, Bui HH, Beavers LS, Farb TB, Ficorilli J, Chesterfield AK, Kuo MS, Bokvist K, Barrett DG, Efanov AM, (2012) Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am J Physiol Endocrinol Metab 303: E1469-E1478.
54. Thomas MJ, Kalivas PW, Shaham Y, (2008) Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol 154: 327-342. (Pubitemid 351670603)
55. Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R, (2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161: 1231-1237. (Pubitemid 38859173)
56. Ueda N, Tsuboi K, Uyama T, (2010) Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801: 1274-1285.
57. Vergara-Moragues E, Gonzalez-Saiz F, Lozano OM, Betanzos Espinosa P, Fernandez Calderon F, Bilbao-Acebos I, Perez Garcia M, Verdejo Garcia A, (2012) Psychiatric comorbidity in cocaine users treated in therapeutic community: substance-induced versus independent disorders. Psychiatry Res 200: 734-741.
58. Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ, (2008) The role of CB1 receptors in psychostimulant addiction. Addict Biol 13: 225-238. (Pubitemid 351692984)